Condition
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Locations
Canada, Czechia, France, Germany, Italy, Japan, Netherlands, Spain,
United States
Start date
20/02/2024
Identifiers
Trial ID
NN6019-7565,
NCT number NCT06260709,
Eudract number Not Available
NCT number NCT06260709,
Eudract number Not Available
Summary
This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for up to 157 weeks (36 months/3 years).
Trial Overview:
Treatment
DRUG: NNC6019-0001
Study type
INTERVENTIONAL
Trial duration
Feb 20 2024 - Aug 15 2028
Participants
80
Phase
II
Are you eligible?
Gender
Male and female
Age
18 to 85 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.